scholarly journals Correlation of Serum Prolactin and Thyroid Hormone in Female Infertility

2019 ◽  
Vol 17 (2) ◽  
pp. 32-34
Author(s):  
Fahat Banu
Keyword(s):  
Thyroid Hormone ◽  
Thyroid Dysfunction ◽  
Female Infertility ◽  
Serum Prolactin ◽  
Psychological Consequences ◽  
Medical College ◽  
Hormone Profile ◽  
Hormonal Imbalance ◽  
High Incidence ◽  
Serum Tsh

Background: Infertility is a growing problem with adverse medical, social and psychological consequences globally. Apart from several causes of infertility, hormonal imbalance especially thyroid dysfunction and hyperprolactinemia can lead to female infertility. Both these conditions are treatable so Proper management of hormonal imbalance can result in restoration of normal fertility. Aims and objectives: Correlation of serum Prolactin and Thyroid hormone in female infertility. Materials and methods: Descriptive hospital based study was conducted at Nepalgunj medical college and teaching hospital, Nepalgunj, Banke, Nepal. The data was collected from September 2018 to August 2019. Total 30 cases of females of primary and secondary infertility attending outpatient department of gynecology department of Nepalgunj medical college were included in the study. A detailed history and clinical evaluation was done along with estimation of serum Prolactin and Thyroid hormone profile. Result: Hormonal status of subjects showed 15 i.e. 50% participants were thyroid whereas 11 (36.33%) were hypothyroid and 4 (13.33%) were hyperthyroid. Serum Prolactin was raised in 17 (57%) and normal in 13 (43%). Serum TSH and prolactin were found to be significantly positively correlated in female infertility (r=0.507, p =0.004). Conclusion: There is a high incidence of hyperprolactinaemia and thyroid dysfunction in female infertility.

scholarly journals Thyroid Hormone Profile and Its Prognostic Impact on the Coronavirus Disease 2019 in Korean Patients

2021 ◽  
Vol 36 (4) ◽  
pp. 769-777
Author(s):  
Jiyeon Ahn ◽  
Min Kyung Lee ◽  
Jae Hyuk Lee ◽  
Seo Young Sohn
Keyword(s):  
Thyroid Hormone ◽  
Disease Severity ◽  
Thyroid Dysfunction ◽  
Severe Disease ◽  
Prognostic Significance ◽  
Thyroid Stimulating Hormone ◽  
Prognostic Impact ◽  
Hormone Profile ◽  
Serum Tsh ◽  
Subclinical Thyrotoxicosis

Background: Data on the association between coronavirus disease 2019 (COVID-19) and thyroid have been reported, including overt thyrotoxicosis and suppression of thyroid function. We aimed to evaluate the thyroid hormone profile and its association with the prognosis of COVID-19 in Korean patients.Methods: The clinical data of 119 patients with COVID-19, admitted in the Myongji Hospital, Goyang, South Korea, were retrospectively evaluated. The thyroid hormone profiles were analyzed and compared based on disease severity (non-severe disease vs. severe to critical disease). Clinical outcomes were analyzed according to the tertiles of thyroid hormones.Results: Of the 119 patients, 76 (63.9%) were euthyroid, and none presented with overt thyroid dysfunction. Non-thyroidal illness syndrome was the most common manifestation (18.5%), followed by subclinical thyrotoxicosis (14.3%) among patients with thyroid dysfunction. Thyroid stimulating hormone (TSH) and triiodothyronine (T3) levels were significantly lower in patients with severe to critical disease than in those with non-severe disease (P<0.05). Patients in the lowest T3 tertile (<0.77 ng/mL) had higher rates of mechanical ventilation, intensive care unit admission, and death than those in the middle and highest (>1.00 ng/mL) T3 tertiles (P<0.05). COVID-19 patients in the lowest T3 tertile were independently associated with mortality (hazard ratio, 5.27; 95% confidence interval, 1.09 to 25.32; P=0.038) compared with those in the highest T3 tertile.Conclusion: Thyroid dysfunction is common in COVID-19 patients. Changes in serum TSH and T3 levels may be important markers of disease severity in COVID-19. Decreased T3 levels may have a prognostic significance in COVID-19 related outcome.

scholarly journals Thyroid function in COVID-19 and the association to cytokine levels and mortality

2021 ◽  
Author(s):  
Clara Lundetoft Clausen ◽  
Åse Krogh Rasmussen ◽  
Trine Holm Johannsen ◽  
Linda Maria Hilsted ◽  
Niels Erik Skakkebæk ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Thyroid Dysfunction ◽  
Thyroid Stimulating Hormone ◽  
Free T4 ◽  
Autoimmune Thyroid Diseases ◽  
Autoimmune Thyroid ◽  
Gm Csf ◽  
Cytokine Levels ◽  
Serum Tsh ◽  
Tsh Levels

The hypothalamic-pituitary-thyroid hormone axis might be affected in COVID-19, but existing studies have shown varying results. It has been hypothesized that hyperinflammation, as reflected by secretion of cytokines, might induce thyroid dysfunction among patients with COVID-19. We explored thyroid hormone involvement in the acute phase of symptomatic COVID-19, and its possible associations with cytokine levels and mortality risk. This was a single-center study of 116 consecutive patients hospitalized for moderate‐to‐severe COVID-19 disease. Serum concentrations of thyroid‐stimulating hormone (TSH), free thyroxine (T4) and 45 cytokines/chemokines were measured in all patients within 3 days of admission. Data were extracted retrospectively through manual review of health records. At admission, 95 (81.9%) were euthyroid, while 21 (18.1%) had a biochemical thyroid dysfunction. This included subclinical thyrotoxicosis (n=11), overt thyrotoxicosis (n=2), hypothyroidism (n=1), non-thyroidal illness (n=2), and normal TSH but high free T4 (n=5). TSH levels were inversely correlated with IL-8 (r = -0.248), IL-10 (r = -0.253), IL-15 (r = -0.213), IP-10 (r = -0.334) and GM-CSF (r = -0.254). Moreover, IL-8 levels, IP-10, and GM-CSF were significantly higher in patients with serum TSH <0.4 mIU/L. Lastly, a twofold increment of IL-8 and IL-10 was associated with significantly higher odds of having TSH <0.4 mIU/L (odds ratio 1.86 [1.11–3.10] and 1.78 [1.03–3.06]). Serum TSH was not associated with 30- or 90-day mortality. In conclusion, this study suggests that fluctuations of TSH levels in patients with COVID-19 may be influenced by circulating IL-8, IL-10, IL-15, IP-10, and GM-CSF, as previously described in autoimmune thyroid diseases.

Hyperthyroidism caused by a pituitary thyrotrophin-secreting tumour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves' disease in a middle-aged woman

1985 ◽  
Vol 110 (3) ◽  
pp. 373-382 ◽  
Author(s):  
Kyuzi Kamoi ◽  
Terunori Mitsuma ◽  
Hiroshi Sato ◽  
Motoharu Yokoyama ◽  
Kazuo Washiyama ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Clinical Signs ◽  
Antithyroid Drug ◽  
Reciprocal Relationship ◽  
Serum Prolactin ◽  
Graves Disease ◽  
Α Subunit ◽  
Thyrotrophin Releasing Hormone ◽  
Aged Woman ◽  
Serum Tsh

Abstract. A 46-year-old woman had signs of thyrotoxicosis and galactorrhoea. Serum immunoreactive TSH and its α-subunit increased in the presence of high serum triiodothyronine (T3), thyroxine (T4), and free T4 concentrations, whereas β-subunit TSH was undetectable. Exogenous TRH failed to increase serum TSH. Serum TSH was markedly suppressed by glucocorticoid, but was increased by antithyroid drug. l-Dopa or bromocriptine partially suppressed, but nomifensine had no influence on serum TSH. Serum prolactin (Prl) was above normal and markedly increased by TRH, but depressed by bromocriptine and not suppressed by nomifensine. Plasma TRH was normal in the hyperthyroid state, but was increased by glucocorticoid and antithyroid drug. Excess thyroid hormone depressed plasma TRH concentrations. Basal serum GH levels were constantly low. Transsphenoidal removal of the tumour normalized serum hormones (T3, T4 free T4, TSH, α-subunit and Prl), and eradicated the clinical signs of hyperthyroidism and galactorrhoea. Histological study of the tumour tissue demonstrated both thyrotrophes and somatotrophes. A reciprocal relationship between serum TSH and T4 concentrations shifted to a higher level before but was normalized after removal of the tumour. Ten months later, the clinical signs of thyrotoxicosis and the increase in serum thyroid hormone recurred without a concomitant increase in serum TSH and its α-subunit. Thyroidal auto-antibodies were slightly positive, but thyrotrophin-binding inhibitor immunoglobulin (TBII) was negative. Administration of antithyroid drug produced a euthyroid state, but 3 years later, discontinuation of the treatment resulted in recurrent hyperthyroidism without suppressed plasma TRH and with no evidence of regrowth of the pituitary tumour. It is suggested that the patient initially had hyperthyroidism owing to excessive TSH secretion from the tumour caused by abnormal TRH secretion, and subsequently had hyperthyroidism owing to Graves' disease.

scholarly journals A Study of Thyroid Profile in Patients with Benign Breast Disease

2019 ◽  
Vol 10 (2) ◽  
pp. 125-130
Author(s):  
Amreen Faruq ◽  
MNA Alam ◽  
F Afsana ◽  
M Haque
Keyword(s):  
Observational Study ◽  
Prolactin Level ◽  
Thyroid Dysfunction ◽  
Prospective Observational Study ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Serum Prolactin ◽  
Serum Prolactin Level ◽  
Medical College ◽  
Thyroid Profile

Background: To observe the association between thyroid dysfunction and benign breast disease. Methods: Prospective observational study conducted in the surgical outpatient department on female patients with benign breast disease from April 2017 to April 2018. Results: Among the 208 female subjects included in the study 14.9% had hypothyroidism and 87.5% were completely symptom free when treated with Thyroxin replacement. Serum Prolactin level was also measured in all the subjects and hyperprolactinemia found in 4.8% with 50% associated with hypothyroidism. Conclusion: Thyroid profile may serve as a useful investigation in the treatment of patients with benign breast disease. Anwer Khan Modern Medical College Journal Vol. 10, No. 2: July 2019, P 125-130

Graves'-Basedow disease in pregnancy

2015 ◽  
Vol 54 (03) ◽  
pp. 106-111 ◽  
Author(s):  
S. L. Andersen ◽  
P. Laurberg
Keyword(s):  
Side Effects ◽  
Birth Defects ◽  
Thyroid Dysfunction ◽  
National Study ◽  
Antithyroid Drugs ◽  
Upper Limit ◽  
Special Concern ◽  
Maternal Thyroid ◽  
Toxic Reactions ◽  
Serum Tsh

SummaryThyroid hormones are essential development factors and maternal thyroid dysfunction may cause pregnancy complications and diseases in the fetus/child. In the present review we discuss new data on the incidence of Graves'-Basedow disease (GBD) in and around pregnancy, and how hyperthyroidism may affect the risk of spontaneous abortion and stillbirth.A special concern in pregnant women is the potential side effects from the use of antithyroid drugs (ATDs). One type of side effects is the allergic/toxic reactions to the drugs, which seem to be similar in and outside pregnancy, and another is that ATDs tend to over treat the fetus when the mother with GBD is made euthyroid. To avoid fetal hypothyroidism, the lowest possible ATD dose should be used to keep maternal thyroid function at the upper limit of normality with low serum TSH. Birth defects after the use of methimazole (MMI) (or its prodrug carbimazole) have been considered to be very rare, and no risk has previously been associated with the use of propylthiouracil (PTU). However, a recent Danish national study found that 1/30 of children exposed to MMI in early pregnancy had birth defects associated with this, and many defects were severe. PTU exposure was associated with defects in 1/40, and these defects were less severe. Proposals are given on how to reduce the risk of ATD associated birth defects.

Comparative Study Between Clean Intermittent Self-Catheterization (Cisc) and Continuous Indwelling Catheterization (Cidc) in Relieving Acute Refractory Retention of Urine Due to Benign Enlargement of Prostate (Bep)

2020 ◽  
Vol 21 (2) ◽  
pp. 105-110
Author(s):  
Md Shawkat Alam ◽  
Sudip Das Gupta ◽  
Hadi Zia Uddin Ahmed ◽  
Md Saruar Alam ◽  
Sharif Muhammod Wasimuddin
Keyword(s):  
Comparative Study ◽  
Acute Urinary Retention ◽  
Bladder Capacity ◽  
Inclusion Criteria ◽  
College Hospital ◽  
Medical College ◽  
High Incidence ◽  
Group A ◽  
Group B ◽  
Better Than

Objective: To compare the clean intermittent self-catheterization (CISC) with continuous indwelling catheterization (CIDC) in relieving acute urinary retention (AUR) due to benign enlargement of prostate (BEP). Materials and Methods :A total 60 patients attending in urology department of Dhaka Medical college hospital were included according to inclusion criteria ,Patients were randomized by lottery into two groups namely group –A and group –B for CISC and IDC drainage respectively . Thus total 60 patients 30 in each group completed study. Results : Most men can safely be managed as out-patients after AUR due to BPH. The degree of mucosal congestion and inflammation within the bladder was found to be lower in those using CISC and the bladder capacity in these patients was also found higher.Patients with an IDC had a high incidence of UTIs then that of patients with CISC. During the period of catheterization the incidence of UTI was 43.3% in group B in comparison to 40% in group A; before TURP 36% in group B in comparison to 10% incidence in group A.According to patient’s opinion CISC is better than IDC in the management of AUR. Experiencing bladder spasm, reporting blood in urine, management difficulties, incidence and severity of pain were less in CISC group, and the method of CISC was well accepted by patients as well as their family members. Conclusion: From the current study it may be suggested that CISC is better technique for management of AUR patient due to BPH than IDC. It can also be very helpful when surgery must be delayed or avoided due to any reasons in this group of patients. Bangladesh Journal of Urology, Vol. 21, No. 2, July 2018 p.105-110

Pituitary responses to a dopamine antagonist at different times of the day in normal women

1982 ◽  
Vol 100 (4) ◽  
pp. 481-485 ◽  
Author(s):  
F. R. Pérez-López ◽  
C. M. González-Moreno ◽  
M. D. Abós ◽  
J. A. Andonegui ◽  
R. H. Corvo
Keyword(s):  
Serum Prolactin ◽  
Dopamine Antagonist ◽  
Hormonal Changes ◽  
Healthy Women ◽  
Serum Lh ◽  
Normal Women ◽  
The Times ◽  
Serum Tsh

Abstract. In order to determine whether or not pituitary responsiveness to the dopaminergic antagonist clebopride changes during the nyctohemeral cycle, 10 healthy women with regular cycles were given 1 mg of clebopride orally at 09.00 h and 24.00 h with at least a 5 day interval between each test. In addition, 5 of the women were given a placebo instead of clebopride at midnight to evaluate the spontaneous hormonal changes. During the 24.00 h test the women had significantly higher P < 0.05) mean TSH basal levels. Serum prolactin (Prl) increased significantly (P < 0.001) after clebopride administration while these changes did not occur when placebo was used instead of clebopride at midnight. The Prl response to clebopride was qualitatively similar at 09.00 h and at 24.00 h. Clebopride given at midnight induced a significant increase (P < 0.05) in serum TSH while this change did not occur when the drug was given at 09.00 h or when placebo was given at midnight. The administration of clebopride resulted in no discernible alterations in serum LH, FSH or GH in either the 09.00 h or the 24.00 h tests. Thus, Prl responses to clebopride were similar in the morning and at midnight, TSH significantly increased after clebopride at midnight whereas this did not occur when the drug was given in the morning, and no significant changes were induced in LH, FSH or GH at the times studied.

Assesment of Maternal Thyroid Hormone Profile and it’s Association with Fetal Outcome

2011 ◽  
Vol 4 (3) ◽  
pp. 357-358
Author(s):  
Dr. Aditi Choubey ◽  
◽  
Dr. T.M. Panchanadikar Dr. T.M. Panchanadikar ◽  
Dr. Alpesh Patel ◽  
Dr. Deven Jogal
Keyword(s):  
Thyroid Hormone ◽  
Fetal Outcome ◽  
Hormone Profile ◽  
Maternal Thyroid

Women’s Infertility - A Ayurvedic thought

2017 ◽  
Vol 2 (4) ◽  
Author(s):  
Sonalika Hiremath ◽  
Santhosh Kumar S. ◽  
Sridevi Swamy
Keyword(s):  
Uterine Fibroid ◽  
Poor Quality ◽  
The State ◽  
Full Term ◽  
Female Infertility ◽  
Cervical Canal ◽  
Fallopian Tubes ◽  
Structural Problems ◽  
Hormonal Imbalance ◽  
Males And Females

Infertility primarily refers to the biological inability of a person to contribute to conception. In women, it may also refer to the state when she is not able to carry a pregnancy to its full term. Female infertility is caused due to structural problems like blocked Fallopian tubes, defect in cervical canal, uterine fibroid or polyps. Hormonal imbalance leading .ovulation problems too can cause infertility. From Ayurvedic perspectives, Shukra Dhatu can get affected by various physical, mental causes and even by serious diseases. Poor quality Shukra Dhatu can cause infertility in males and females.

Sign in / Sign up

Export Citation Format

Share Document